Prevention of disease progression in Leishmania infantum-infected dogs with dietary nucleotides and active hexose correlated compound

Table 2 Changes in lymphocyte counts and cytokine levels measured in each group during the study, expressed as mean ± standard deviation (ANCOVA)

Parameter	Supplement group	Placebo group	P-value supplement vs placebo (ANCOVA)
CD4+: %
0 days	17.69 ± 15.37	13.94 ± 11.62	–
60 days	19.45 ± 15.14	14.69 ± 12.40	0.752
180 days	23.57 ± 12.45	19.89 ± 11.12	0.861
365 days	26.33 ± 9.95	24.07 ± 9.53	0.643
CD8+: %
0 days	12.60 ± 13.48	7.65 ± 8.63	–
60 days	11.65 ± 10.40	8.16 ± 9.04	0.981
180 days	13.72 ± 12.39	7.76 ± 5.38	0.578
365 days	12.44 ± 6.76	10.76 ± 6.33	0.546
CD4+/CD8+ ratio
0 days	2.01 ± 1.39	2.80 ± 1.90	–
60 days	2.41 ± 2.12	2.31 ± 1.33	0.394
180 days	3.10 ± 3.15	2.92 ± 1.50	0.238
365 days	3.21 ± 3.43	2.75 ± 1.11	0.721
IL-6: pg/ml
0 days	382.91 ± 940.53	269.95 ± 1054.1	–
60 days	138.65 ± 371.02	393.12 ± 1424.6	0.165
180 days	192.38 ± 456.17	118.67 ± 184.77	0.728
365 days	314.92 ± 1024.5	34.63 ± 55.48	0.612
IL-10: pg/ml
0 days	22.69 ± 76.01	17.92 ± 63.47	–
60 days	7.52 ± 12.67	38.51 ± 147.25	0.208
180 days	4.33 ± 4.34	69.35 ± 231.80	0.172
365 days	6.53 ± 10.01	2.68 ± 0.74	0.282
TNF-α: pg/ml
0 days	123.14 ± 292.94	81.58 ± 308.77	–
60 days	40.47 ± 95.60	112.17 ± 397.27	0.150
180 days	59.21 ± 144.19	44.82 ± 72.46	0.811
365 days	73.11 ± 233.46	13.23 ± 19.81	0.597
IFN-γ: pg/ml
0 days	15.97 ± 35.87	3.49 ± 8.12	–
60 days	7.04 ± 13.64	1.39 ± 2.33	0.264
180 days	0.81 ± 0.84	0.84 ± 0.42	0.980
365 days	4.58 ± 13.43	1.30 ± 0.97	0.544

ISSN: 1756-3305